Liraglutide vs Tirzepatide: Head-to-Head Comparison
Liraglutide was the first GLP-1 agonist approved for obesity, producing ~8% weight loss with daily dosing. Tirzepatide is a newer dual GIP/GLP-1 agonist achieving up to 22.5% weight loss with weekly dosing. Tirzepatide is significantly more effective but liraglutide has a longer safety track record.
Approved options in this comparison
Liraglutide is currently modeled on this site as an approved treatment path for: Type 2 diabetes mellitus (Victoza); chronic weight management in adults with BMI ≥30 or ≥27 with comorbidities (Saxenda). Brand names in the current dataset: Victoza, Saxenda.
Tirzepatide is currently modeled on this site as an approved treatment path for: Type 2 diabetes mellitus; chronic weight management in adults with obesity or overweight with comorbidities. Brand names in the current dataset: Mounjaro, Zepbound.
Need help choosing between prescribing paths?
One or more options in this comparison are currently modeled on this site as approved treatment paths. Use the provider matcher to narrow the best next step based on your budget, insurance, and timeline.
Find a providerApproved product paths, cost friction, provider routing, and tracker next steps in one source-backed hub.
Open treatment hub ->Approved product paths, cost friction, provider routing, and tracker next steps in one source-backed hub.
Open treatment hub ->Side-by-Side Comparison
| Dimension | Liraglutide | Tirzepatide |
|---|---|---|
| Evidence Level | Level A — 10+ years of clinical data (SCALE, LEADER) | Level A — large Phase 3 programs (SURMOUNT, SURPASS) |
| FDA Status | Approved for T2D (Victoza) and obesity (Saxenda) | Approved for T2D (Mounjaro) and obesity (Zepbound) |
| Weight Loss Efficacy | ~8% mean body weight loss (Saxenda 3.0 mg) | Up to 22.5% mean body weight loss (Zepbound 15 mg) |
| Dosing Convenience | Daily subcutaneous injection | Once weekly subcutaneous injection |
| Mechanism | GLP-1 receptor agonist only | Dual GIP + GLP-1 receptor agonist |
| Long-Term Safety | 10+ years of real-world data; well-established profile | Newer agent; ~3 years post-approval data |
Peptide Overviews
Liraglutide
AFDA ApprovedLiraglutide is a GLP-1 receptor agonist approved by the FDA for type 2 diabetes (Victoza) and chronic weight management (Saxenda). It was the first GLP-1 agonist approved specifically for obesity.
Tirzepatide
AFDA ApprovedTirzepatide is the first dual GIP and GLP-1 receptor agonist, approved by the FDA for type 2 diabetes (Mounjaro) and chronic weight management (Zepbound). Achieves unprecedented weight loss in clinical trials.
GLP-1 Support Essentials
Products that can support side-effect management, hydration, and protein intake.
LMNT Electrolyte Packets
Sodium-focused electrolytes to prevent dehydration and fatigue common in early GLP-1 therapy.
High-Protein Shakes (30g)
Convenient protein shakes to maintain muscle mass on reduced GLP-1 caloric intake.
Metamucil Fiber Supplement
Soluble fiber powder to manage constipation and GI side effects during GLP-1 treatment.
Vitamin B12 (Methylcobalamin 1000mcg)
GLP-1 agonists can reduce B12 absorption over time — methylcobalamin is the most bioavailable form.
Ginger Chews for Nausea
Natural nausea relief for the dose-escalation adjustment period, particularly weeks 1–4.
Unflavored Whey Protein Isolate
Preserve lean mass without excess carbs or calories when appetite is suppressed.
Amazon affiliate links; we may earn a small commission at no extra cost to you. See our disclosure.
Recommended Reading
Books covering peptide science, longevity research, and biohacking frameworks.
The Peptide Protocols
Comprehensive reference for peptide mechanisms, dosing research, and clinical applications.
Boundless by Ben Greenfield
Covers peptides, nootropics, hormones, and longevity strategies in an optimization framework.
Lifespan by David Sinclair
Evidence-based deep-dive into aging science, directly relevant to longevity peptide research.
The Longevity Paradox
Gut-centric aging research with diet and supplementation protocols for extending healthspan.
Amazon affiliate links; we may earn a small commission at no extra cost to you. See our disclosure.
Liraglutide vs Tirzepatide: FAQ
Stay informed on peptide comparisons
Get weekly comparison updates, new study alerts, and regulatory changes.
No spam. Unsubscribe anytime.
Medical Disclaimer
This content is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations.
Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment. Do not disregard professional medical advice based on information found on this site.
No claims of therapeutic efficacy are made for substances that are not FDA-approved for the discussed indications. Research citations reflect published findings and do not imply endorsement.